

I. Requirements for Prior Authorization of Immunosuppressives, Oral

A. Prescriptions That Require Prior Authorization

Prescriptions for Immunosuppressives, Oral that meet any of the following conditions must be prior authorized:

1. A non-preferred Immunosuppressive, Oral. See the Preferred Drug List (PDL) for the list of preferred Immunosuppressives, Oral at: <https://papdl.com/preferred-drug-list>.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Immunosuppressive, Oral, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. Is prescribed the Immunosuppressive, Oral for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Does not have a contraindication to the requested medication; **AND**
4. For Lupkynis (voclosporin), **all** of the following:
 - a. For the treatment of lupus nephritis, has a diagnosis of active lupus nephritis that is confirmed by a kidney biopsy unless a kidney biopsy is not medically advisable,
 - b. Is prescribed Lupkynis (voclosporin) by or in consultation with an appropriate specialist (e.g., nephrologist, rheumatologist),
 - c. Is prescribed Lupkynis (voclosporin) in combination with background immunosuppressive therapy as tolerated,
 - d. Is not prescribed Lupkynis (voclosporin) in combination with cyclophosphamide or Benlysta (belimumab);

AND

5. For all other non-preferred Immunosuppressives, Oral, **one** of the following:
 - a. Has a documented history of therapeutic failure of or a contraindication or an intolerance to the preferred Immunosuppressives, Oral approved or medically accepted for the beneficiary's diagnosis
 - b. Has a current history (within the past 90 days) of being prescribed the same non-preferred Immunosuppressive, Oral;

AND

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Immunosuppressive, Oral. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

LUPKYNIS (voclosporin) PRIOR AUTHORIZATION FORM

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		# of pages: _____		Prescriber name:	
Name of office contact:				Specialty:	
Contact's phone number:				NPI:	State license #:
LTC facility contact/phone:				Street address:	
Beneficiary name:				Suite #:	City/state/zip:
Beneficiary ID#:		DOB:		Phone:	Fax:

CLINICAL INFORMATION

Medication:	<input type="checkbox"/> Lupkynis capsule <input type="checkbox"/> Lupkynis _____	Strength:	Quantity per fill:	Refills:
Directions:				
Diagnosis:			Dx code (<u>required</u>):	
Is Lupkynis prescribed by or in consultation with a specialist, such as a nephrologist or rheumatologist?			<input type="checkbox"/> Yes <i>Submit documentation of consultation with specialist, if applicable.</i> <input type="checkbox"/> No	
Does the beneficiary have kidney or liver impairment that necessitates an adjustment of the dose of Lupkynis?			<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No	
Does the beneficiary have a diagnosis of lupus nephritis that is confirmed by kidney biopsy?			<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No	
Will the beneficiary be taking Lupkynis in addition to background immunosuppressive therapy? Check all that apply. <input type="checkbox"/> mycophenolate mofetil/mycophenolic acid <input type="checkbox"/> prednisone or other corticosteroid <input type="checkbox"/> other (list): _____ _____			<input type="checkbox"/> Yes <i>Submit documentation of complete current medication list.</i> <input type="checkbox"/> No	

PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

NON-PREFERRED MEDICATION PRIOR AUTHORIZATION FORM (form effective 01/01/20)

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			Suite #:	City/State/Zip:
Beneficiary ID#:	DOB:	Phone:	Fax:	
Medication will be billed via: <input type="checkbox"/> Pharmacy <input type="checkbox"/> Medical (Jcode: _____)			Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's Office <input type="checkbox"/> Home <input type="checkbox"/> Other	

Please refer to <https://papdl.com/preferred-drug-list> for the list of preferred and non-preferred medications in each Preferred Drug List class.

Non-preferred medication name:		Dosage form:	Strength:
Directions:		Quantity:	Refills:
Diagnosis <i>(submit documentation)</i> :		Dx code <i>(required)</i> :	
Has the beneficiary taken the requested non-preferred medication in the past 90 days? <i>(submit documentation)</i> <input type="checkbox"/> Yes <input type="checkbox"/> No			
Describe all applicable medical reasons the beneficiary cannot use the preferred medication(s) in the same Preferred Drug List class. Submit documentation (e.g., recent chart/clinic notes, diagnostic evaluations, lab results, etc.) supporting this non-preferred request.			
<input type="checkbox"/> Treatment failure or inadequate response with preferred medication(s) <i>(include drug name, dose, and start/stop dates)</i> :			

<input type="checkbox"/> Unacceptable side effects, hypersensitivities, or other intolerances to preferred medication(s) <i>(include description and drug name(s))</i> :			

<input type="checkbox"/> Contraindication to preferred medication(s) <i>(include description and drug name(s))</i> :			

<input type="checkbox"/> Unique clinical or age-specific indications supported by FDA approval or medical literature <i>(describe)</i> :			

<input type="checkbox"/> Absence of preferred medication(s) with appropriate formulation <i>(list medical reason formulation is required)</i> :			

<input type="checkbox"/> Drug-drug interaction with preferred medication(s) <i>(describe)</i> :			

<input type="checkbox"/> Other medical reason(s) the beneficiary cannot use the preferred medication(s) <i>(describe)</i> :			

<input type="checkbox"/> For renewal requests of previously approved medications, submit documentation of tolerability and beneficiary's clinical response.			

PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.